Trials / Recruiting
RecruitingNCT05876065
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
Efficacy and Safety of Capecitabine and Cyclophosphamide (XC) Versus Physician's Choice as Maintenance Therapy for Advanced Breast Cancer: a Randomized, Controlled, Open-label Clinical Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 86 (estimated)
- Sponsor
- Wenjin Yin · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the efficacy and safety of capecitabine and cyclophosphamide (XC) versus physician's choice as maintenance therapy for patients with advanced breast cancer who achieved disease control after salvage treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XC | Capecitabine (bid po, d1-14) and cyclophosphamide (qd po, d1-d14) every 21 days |
| DRUG | TPC | Any physician's choice as maintenance therapy (except for XC regimen) |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2026-06-01
- Completion
- 2027-02-01
- First posted
- 2023-05-25
- Last updated
- 2025-09-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05876065. Inclusion in this directory is not an endorsement.